Pharmacy Times August 19, 2024
The biosimilar space continues to grow, with key focuses around retina and oncology, but adoption remains slow in the United States.
Biosimilars are considered highly similar to the reference biologics, while improving affordability and accessibility for patients. The potential cost savings of biosimilars are widely discussed, with many experts feeling that the space still has potential that remains unmet. Even with the FDA regulations of biosimilars, which ensure that biosimilars have comparable safety and efficacy to the reference product, there is limited uptake from prescribers. Prescribers and patients continue to express concern about the safety and efficacy of biosimilars compared with the reference product.1
Below are 5 key facts about biosimilars, recapping the current landscape of biosimilars as well as...
Today's Sponsors
Today's Sponsor